Defect in activation-induced cell death in non-obese diabetic (NOD) T lymphocytes

Journal of Autoimmunity

Volumn 20, Issue 3, 2003, Pages 219-226

  Decallonne, Brigitte ^a   Van Etten, Evelyne ^a   Giulietti, Annapaula ^a   Casteels, Kristina ^a   Overbergh, Lutgart ^a   Bouillon, Roger ^a   Mathieu, Chantal ^a,b  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b Onderwijs and Navorsing   (Belgium)

Author keywords

AICD; NOD mouse; Type 1 diabetes

Indexed keywords

ANTIGEN; AUTOANTIGEN; CASPASE 8; CD4 ANTIGEN; CD8 ANTIGEN; FAS ANTIGEN; FASL ANTIGEN; INTERLEUKIN 2; PROTEIN BCL XL; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DEATH; CONTROLLED STUDY; DIABETES MELLITUS; ENZYME ACTIVATION; FEMALE; FLUORESCENCE; GENE EXPRESSION; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE;

EID: 0038062649     PISSN: 08968411     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0896-8411(03)00025-8     Document Type: Article

References (37)

1. Van Parijs L., Abbas A.K. Homeostasis and self-tolerance in the immune system: turning lymphocytes off. Science. 280:1998;243-248.
2. 3restores defect. Diabetes. 47:1998;1033-1037.
3. 3restores sensitivity to cyclophosphamide-induced apoptosis in non-obese diabetic (NOD) mice and protects against diabetes. Clin Exp Immuno. 112:1998;181-187.
4. Colucci F., Cilio C., Leijon K., Penha Goncalves C., Bergman M.L., Holmberg D. Programmed cell death in the pathogenesis of murine IDDM: resistance to apoptosis induced in lymphocytes by cyclophosphamide. J Autoimmun. 9:1996;271-276. doi:10.1006/jaut.1996.0034.
5. Radosevic K., Casteels K.M., Mathieu C., van Ewijk W., Drexhage H., Leenen W. Splenic dendritic cells from the nonobese diabetic mouse induce a prolonged proliferation of syngeneic T cells. A role for an impaired apoptosis of NOD T cells? J Autoimmun. 13:1999;373-382. doi:10.1006/jaut.1999.0338.
6. Leijon K., Hammarstrom B., Holmberg D. Nonobese diabetic (NOD) mice display enhanced immune responses and prolonged survival of lymphoid cells. Int Immunol. 6:1994;339-345.
7. Kishimoto H., Sprent J. A defect in central tolerance in NOD mice. Nature Immunol. 2:2001;1025-1031.
8. Zipris D., Lazarus A., Crow A., Hadzija M., Delovitch T. Defective thymic T cell activation by concanavalin A and anti-CD3 in autoimmune nonobese diabetic mice. J Immunol. 146:1991;3763-3771.
9. Serreze D., Leiter E. Defective activation of T suppressor cell function in nonobese diabetic mice. J Immunol. 140:1988;3801-3807.
10. Zhang J., Salojin K., Delovitch T. CD28 co-stimulation restores T cell responsiveness in NOD mice by overcome deficiencies in Rac-1/p38 mitogen-activated protein kinase signaling and IL-2 and IL-4 gene transcription. Int Immunol. 13:2001;377-384.
11. Rasanen L., Hyoti H., Lehto M., Kallioniemi O., Antonen J., Huuponen T., Karjalainen J., Leiniki P. Defective autologous mixed leucocyte reaction in newly diagnosed type 1 diabetes mellitus. Clin Exp Immunol. 71:1988;470-474.
12. De Maria R., Todaro M., Stassi G., Di Blasi F., Giordano M., Galluzzo A., Giordano C. Defective T cell receptor/CD3 complex signalling in human type I diabetes. Eur J Immunol. 24:1994;999-1002.
13. lckexpression in T lymphocytes from type 1 diabetic patients. J Immunol. 165:2000;5874-5883.
14. Dosch H.M., Cheung R., Karges W., Pietropaolo M., Becker D. Persistent T cell anergy in human type 1 diabetes. J Immunol. 163:1999;6933-6940.
15. Serreze D., Gaskins H., Leiter E. Defects in the differentiation and function of antigen presenting cells in NOD/Lt mice. J Immunol. 150:1993;2534-2543.
16. Piganelli J., Martin T., Haskins K. Splenic macrophages from the NOD mouse are defective in the ability to present antigen. Diabetes. 47:1998;1212-1218.
17. Pozilli P., Signore A., Williams A., Beales P. NOD mouse colonies around the world - recent facts and figures. Immunol Today. 14:1993;193-196.
18. Overbergh L., Valckx D., Waer M., Mathieu C. Quantification of murine cytokine mRNAs using real time quantitative reverse transcriptase PCR. Cytokine. 11:1999;305-312. doi: 10.1006/cyto.1998.0426.
19. Decallonne B., Overbergh L., Casteels K.M., Gysemans C., Bouillon R., Mathieu C. Streptococcal wall component OK432 restores sensitivity of non-obese diabetic (NOD) thymocytes to apoptosis signals. Diabetologia. 43:2000;1302-1308.
20. Van Parijs L., Refaeli Y., Abbas A., Baltimore D. Autoimmunity as a consequence of retrovirus-mediated expression of c-FLIP in lymphocytes. Immunity. 11:1999;763-770.
21. Krammer P. CD95's deadly mission in the immune system. Nature. 407:2000;789-795.
22. Zhang X., Brunner T., Carter L., Dutton R., Rogers P., Bradley L., Sato T., Reed J., Green D., Swain S. Unequal death in T helper cell (Th)1 and Th2 effectors: Th1, but not Th2, effectors undergo rapid Fas/Fas-L mediated apoptosis. J Exp Med. 185:1997;1837-1849.
23. Nishimura-Morita Y., Nose M., Inoue T., Yonehara S. Amelioration of systemic autoimmune disease by the stimulation of apoptosis-promoting receptor Fas with anti-Fas mAb. Int Immunol. 9:1997;1793-1799.
24. Giordano C., De Maria L., Stassi G., Todaro M., Richiusa P., Giordano M., Testi R., Galluzzo A. Defective expression of the apoptosis-inducing CD95 (Fas/APO-1) molecule on T and B cells in IDDM. Diabetologia. 38:1995;1449-1454.
25. DeFranco S., Bonissimo S., Cerutti F., Bona G., Bottarel F., Cadario F., Brusco A., Loffredo G., Rabbone I., Corrias A., Pignata C., Ramenghi U., Dianzani U. Defective function of Fas in patients with type 1 diabetes associated with other autoimmune diseases. Diabetes. 50:2001;483-488.
26. Lenardo M. Interleukin-2 programs mouse alpha beta T lymphocytes for apoptosis. Nature. 353:1991;858-861.
27. Van Parijs L., Refaeli Y., Lord J., Nelson B., Abbas A., Baltimore D. Uncoupling IL-2 signals that regulate T cell proliferation, survival, and Fas-mediated activation-induced cell death. Immunity. 11:1999;281-288.
28. Li X., Demirci G., Ferrari-Lacraz S., Groves C., Coyle A., Malek T., Strom T. IL-15 and IL-2: a matter of life and death for T cells in vivo. Nature. 7:2001;114-118.
29. Serreze D., Hamaguchi K., Leiter E. Immunostimulation circumvents diabetes in NOD/Lt mice. J Autoimm. 2:1989;759-776.
30. Chandy K., Charles A., Kershnar A., Buckingham B., Waldeck N., Gupta S. Autologous mixed lymphocyte reaction in man: Cellular and molecular basis of deficient autologous mixed lymphocyte response in insulin-dependent diabetes mellitus. J Clin Immunol. 4:1984;424-428.
31. Giordano C., Panto F., Caruso C., Modica M.A., Zambito A.M., Sapienza N., Amato M.P., Galluzzo A. Interleukin 2 and soluble interleukin 2-receptor secretion defect in vitro in newly diagnosed type I diabetic patients. Diabetes. 38:1989;310-315.
32. Gorelik L., Flavell R. Abrogation of TGFbeta signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity. 12:2000;171-181.
33. Chen W., Jin W., Tian H., Sicurello P., Frank M., Orenstein J., Wahl S. Requirement for transforming growth factor β1 in controlling T cell apoptosis. J Exp Med. 194:2001;439-453.
34. Genestier L., Kasibhatla S., Brunner T., Green D.R. Transforming growth factor beta 1 inhibits Fas ligand expression and subsequent activation-induced cell death in T cells via downregulation of c-Myc. J Exp Med. 189:1999;231-239.
35. Cerwenka A., Kovar H., Majdic O., Holter W. Fas- and activation-induced apoptosis are reduced in human T cells preactivated in the presence of TGF-beta 1. J Immunol. 156:1996;459-464.
36. Kretowsky A., Maciej K., Ida K. The analysis of in vitro transforming growth factor-beta1 (TGF-beta1) production by peripheral blood in overt and pre-clinical diabetes mellitus. Immunol Lett. 71:2000;85-89.
37. Lamhamedi-Cherradi S.E., Luan J.J., Eloy L., Fluteau G., Bach J.F., Garchon H.J. Resistance of T-cells to apoptosis in autoimmune diabetic (NOD) mice is increased early in life and is associated with dysregulated expression of Bcl-x. Diabetologia. 41:1998;178-184.